Abstract:Angiotensin converting enzyme-2 (ACE-2) is the cell-surface receptor enabling viral uptake of corona virus 2019 (SARS-CoV-2), thus ACE-2 is a first step towards COVID-19 disease. ACE-2 is a metalloenzyme located primarily on the apical surface, and serves as the entry point also for other coronaviruses, including HCoV-NL63 and SARS-CoV. Throughout evolution, ACE-2 precedes renin, suggesting that ACE-2's role changed over time.1 The renin angiotensin system (RAS) and COVID-19 are intertwined.2 Thus, various concerns come up regarding the safety of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) for COVID-19 patients. Interestingly, analogous concerns have not been raised for the Middle-East Respiratory Syndrome (MERS), although MERS is also caused by a corona virus that is incorporated into cells, yet not by ACE-2, but by dipeptidyl peptidase-4.3 Novel coronavirus pneumonia is a new type of infectious disease, caused by SARS-CoV-2. The lungs are the first and primarily affected target organs of SARS-CoV-2. After infecting the lungs, the infiltrating viruses may enter the circulation and reach the kidneys, where they can accumulate and damage resident cells.4 Impaired glomerular filtration also occurs, usually manifested by increased blood creatinine and urea nitrogen levels, and moderate proteinuria. The incidence of reported acute kidney injury varies widely because of the different populations included in different studies, and is approximately 0.1%-29%. High expression of ACE-2 in the kidney, especially in podocytes and proximal tubular epithelial cells, may be related to the susceptibility of renal parenchymal cells and direct viral invasion of the renal parenchyma after COVID-19 infection. However, in fact live virus have not been recovered from urine and viral mRNA has not been amplified from kidney biopsies. Under physiological conditions, ACE-2 converts ANGII to angiotensin (1-7). Angiotensin (1-7) changes the balance from ANGII-induced vasoconstriction to Mas receptor-activated vasodilation after extensive binding to Mas receptors. In addition, activation of the angiotensin (1-7)/ACE-2 axis inhibits the production of reactive oxygen species and downregulates secretion of pro-inflammatory cytokines. Accordingly, binding of SARS-CoV-2 to ACE-2 may weaken the activity of the latter and shift ACE/ACE-2 balance to a state of enhanced ANGII activity, which leads to vasoconstriction and inflammatory5 and oxidative organ damage, and further promotes damage.6 The use of RAS inhibitors can increase expression of ACE-2 on the tissue and apical surface to a certain extent. Therefore, the use of ACEIs or ARBs to treat diseases is considered likely to increase the risk of SARS-CoV-2 exposure. However, so far, there is no experimental evidence indicating that ACEIs or ARBs augment the susceptibility to SARS-CoV-2 or aggravate the outcomes and severity of COVID-19. Accordingly, large observational studies have not shown any association with increased COVID-19 risk and patients who are receiving ACE inhibitors or ARBs.7 After SARS-CoV infection in mice, ACE-2 protein levels are greatly reduced, depending on virus replication, which is consistent with the situation in host cells.8 Additionally, SARS-CoV-2 can weaken the activity of ACE-2 by binding to ACE-2. In consequence, elevated ANGII further aggravates kidney injury by activating AT1R, causing inflammation and fibrosis. Inhibiting RAS by ACEIs/ARBs or recombinant ACE-2 increases expression of ACE-2, thereby reducing ANGII levels and enhancing Ang-(1-7) generation. Increased ACE-2 expression promotes the activation of Mas receptor (MasR), which in turn attenuates inflammation and fibrosis, and therefore attenuates kidney injury.9 Moreover, the increase in the level of soluble ACE-2 may also neutralize SARS-CoV-2, limit virus entry and reduce tissue damage. Therefore, providing RAS inhibitors seems advantageous for COVID-19 patients (Figure 1A). Indeed, observational cohort studies, and randomized trials for other endpoints provide no evidence for adverse effects RAS inhibition in COVID-19.7 Thus, RAS inhibitors should not be withheld from patients because of any SARS-CoV-2 concerns.10, 11 The contrary may hold true. Monteil et al12 reported that infection with SARS-CoV-2 can be inhibited with a human recombinant soluble ACE-2 (hrsACE-2). The hrsACE-2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1000-5000. The investigators also showed that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE-2. Other sophisticated approaches are suggested by Chan et al13 By using deep mutagenesis, that group identified mutations in ACE-2 that increased spike protein binding across the interaction surface, in the asparagine 90-glycosylation motif, and at buried sites. The mutational landscape provided the group with a blueprint for understanding the specificity of the interaction between ACE-2 and spike protein, as well as for engineering high-affinity decoy receptors. Combining mutations brought up ACE-2 variants affinities that rival those of monoclonal antibodies. A stable dimeric variant reveals potent SARS-CoV-2 and SARS-CoV neutralization in vitro. The engineered soluble ACE-2 receptor was catalytically active, and its close similarity with the native receptor could limit the potential for viral escape (Figure 1B). These novel approaches could help us therapeutically in the future. We would like to thank the support of Zhejiang Provincial Key Laboratory of Immunity and Inflammatory diseases. The authors declare no conflict of interest.

Losartan and enalapril maleate differently influence SARS-CoV-2-infected vero cells

Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells

Distinct Mechanisms for TMPRSS2 Expression Explain Organ-Specific Inhibition of SARS-CoV-2 Infection by Enzalutamide

Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19

Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System

The impact of ACE inhibitors on the risk of SARS-CoV-2 virus infection and the course of COVID-19 disease

The effect of renin–angiotensin–aldosterone system inhibitors on organ-specific ace2 expression in zebrafish and its implications for COVID-19

Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial

SARS‐CoV‐2 Effects on the Renin‐angiotensin‐aldosterone System, Therapeutic Implications

Renin–angiotensin System Blockers and Susceptibility to COVID-19: an International, Open Science, Cohort Analysis

Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review

SARS-CoV-2: ACE inhibitors, disastrous or desirable?

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19

Could Renin–angiotensin–aldosterone System Inhibitors Be Used for Hypertensive Patients with Coronavirus Disease 2019?

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study

The effect of zofenopril on the cardiovascular system of spontaneously hypertensive rats treated with the ACE2 inhibitor MLN-4760

Timing matters in the use of renin-angiotensin system modulators and COVID-related cognitive and cerebrovascular dysfunction

Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome